Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Total Debt
Short-term and long-term borrowings combined.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt of $1.03M in Q2 FY2026
Q2 FY2026 total debt was $1.03M.
Context
- Total debt amounted to 0.2% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 1.22M USD
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.22M | — |
Total Debt vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 total debt of $1.03M is the 4th highest of the 5 companies compared; the peer median is $31.21M.
- Total debt amounts to 0.2% of total assets for COAG, versus a peer median of 4.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $63.32M | -4.3% | +55.4% | 8.1% | |
IRONDisc Medicine, Inc. | Sep 2026 | $61.09M | +97.2% | +11.8% | 8.7% |
DMRADamora Therapeutics, Inc. | Mar 2026 | $1.34M | -6.4% | -56.1% | 0.3% |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $1.03M | — | — | 0.2% |
| Mar 2026 | $154K | +32.8% | -31.8% | 0.3% | |
| Peer median (excluding COAG) | $31.21M | +14.2% | -10.0% | 4.2% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.